www.astro.org
Abstract # 2303 A Pretreatment PSA Level of 7 to 10 Ng/ml is an Independent Predictor of Adverse Biochemical Disease Free Survival among Low Risk Prostate Cancer Patients Treated with I-125 Brachytherapy

Presenter: Cesaretti, Jamie

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

About the Presenter:
During medical school training at the State University of New York at Stony Brook, he developed an avid interest in Radiation Oncology. His training continued after medical school with an Internal Medicine internship at the St. Luke’s-Roosevelt hospital center in New York followed by his Radiation Oncology Residency at the Mount Sinai School of Medicine. During his training, he did 400 prostate brachytherapy implants and completed a pediatrics and external beam prostate/ radiosurgery rotations at the Memorial Sloan Kettering Cancer Center. After completion of his residency, he was appointed to the faculty of the Mount Sinai School of Medicine in 2004. During his professorship, he studied the reasons behind why patients develop side effects during and following radiation therapy for prostate cancer. The Department of Defense awarded Dr. Cesaretti a large grant that allowed him to complete important investigations in this area. He and his research group were also awarded funding by the American Cancer Society, the National Institutes of Health, and the American Society of Therapeutic Radiology and Oncology. Dr. Cesaretti joined FROG in 2008. (http://www.frogdocs.com/) He has a special interest in the application of both stereotactic body radiosurgery and prostate brachytherapy. In addition, he is a member of the Children’s Oncology Group, the American Society of Therapeutic Radiology and Oncology and the American Brachytherapy Society. He has given many talks about how to successfully cure prostate cancer using seed implants in Japan, South Africa, Spain, Italy, Germany, and throughout the United States. He has authored many papers, written several protocols, and contributed the prostate brachytherapy chapters to textbooks about the treatment of prostate cancer. He also has a particular interest in helping patients make the right personal decision regarding their cancer care among an often-overwhelming array of potential treatment choices.

Authors:
J. A. Cesaretti, N. N. Stone, J. Kao, R. G. Stock, Mount Sinai School of Medicine, New York, NY

Author Disclosure:
  J.A. Cesaretti, C.R.BARD, D. Speakers Bureau/Honoraria; N.N. Stone, Prologics Inc., E. Ownership Interest; J. Kao, None; R.G. Stock, None.


E-mail a friend about this abstract:
Enter email address: